These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17538986)

  • 21. Update in inflammatory bowel disease.
    Morrison G; Headon B; Gibson P
    Aust Fam Physician; 2009 Dec; 38(12):956-61. PubMed ID: 20369146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
    Ochsenkühn T; Sackmann M; Göke B
    Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective leukocyte apheresis for the treatment of inflammatory bowel disease.
    Abreu MT; Plevy S; Sands BE; Weinstein R
    J Clin Gastroenterol; 2007; 41(10):874-88. PubMed ID: 18090155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nutrition in inflammatory bowel disease].
    Lee KM
    Korean J Gastroenterol; 2008 Jul; 52(1):1-8. PubMed ID: 19077484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for the management of inflammatory bowel disease in adults.
    Carter MJ; Lobo AJ; Travis SP;
    Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
    MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
    [No Abstract]   [Full Text] [Related]  

  • 28. An Update on Inflammatory Bowel Disease.
    Sairenji T; Collins KL; Evans DV
    Prim Care; 2017 Dec; 44(4):673-692. PubMed ID: 29132528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prospects of the biological therapy of inflammatory bowel diseases].
    Parfenov AI
    Eksp Klin Gastroenterol; 2005; (1):38-43. PubMed ID: 15991851
    [No Abstract]   [Full Text] [Related]  

  • 30. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
    Trivedi I; Hanauer SB
    Expert Opin Drug Saf; 2015; 14(12):1915-34. PubMed ID: 26559664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 32. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
    Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F;
    Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic inflammatory diseases in the child].
    Cucchiara S; Fecarotta S; Gaudiello G; Terrin G
    Minerva Pediatr; 2000 Sep; 52(9):445-50. PubMed ID: 11126649
    [No Abstract]   [Full Text] [Related]  

  • 34. [Inflammatory bowel diseases in children].
    Dupont C
    Ann Gastroenterol Hepatol (Paris); 1995 Sep; 31(4):237-53. PubMed ID: 7486821
    [No Abstract]   [Full Text] [Related]  

  • 35. New therapies for inflammatory bowel disease: from the bench to the bedside.
    Danese S
    Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
    Pijls PA; Gilissen LP
    Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universal-access healthcare system.
    Benchimol EI; To T; Griffiths AM; Rabeneck L; Guttmann A
    J Pediatr; 2011 Jun; 158(6):960-967.e1-4. PubMed ID: 21227449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory bowel disease.
    Jenner C
    Practitioner; 1991 Mar; 235(1500):256-61. PubMed ID: 1852710
    [No Abstract]   [Full Text] [Related]  

  • 40. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia.
    Talley NJ
    Am J Gastroenterol; 2009 Jun; 104(6):1339-41. PubMed ID: 19491845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.